© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Bumetanide stands out as a high-potency loop diuretic, long relied on across pharmaceutical and chemical industries for its precise electrolyte management effect. Derived from benzoic acid, its primary impact unfolds through efficient inhibition of sodium and chloride reabsorption in the ascending limb of the loop of Henle in the kidneys. This action translates into robust management of fluid retention associated with heart failure, renal disease, and liver dysfunction. Its synonyms in supply chains might include descriptors like “raw material, white crystalline solid, and pharmaceutical grade powder,” tying together chemical identity and operational intent in one concise scope.
Bumetanide’s molecular formula is C17H20N2O5S, and its molecular weight clocks in around 364.4 g/mol. Structurally, the molecule features a sulfonamide group attached to a substituted benzoic acid, connected via an ethylamino bridge. Crystallographic analyses highlight its rigid backbone and various functional groups, which reinforce its polarity, reactivity, and high solubility in methanol, DMSO, and ethanol. Suppliers recognize the value embedded in its chemical structure—a blend of benzene rings, sulfonyl moieties, and carboxylic acid functionalities—yielding a material both stable and reactive under specific synthetic conditions.
In its most common physical state, bumetanide presents as a white or off-white crystalline solid or powder. Handlers notice it feels dry and light to the touch, with density averaging between 1.54–1.57 g/cm³. It typically does not exist as a liquid or pearl, distinguishing itself from hydrous or oil-based chemicals. Its melting point ranges from about 202°C to 204°C, which is integral for formulation scientists working on controlled-release or stability-sensitive blends. Moisture sensitivity turns up with improper storage, signaling that tight container seals and dry conditions matter for safe, long-term handling of the solid form.
Commercially available bumetanide usually reaches purity levels above 98%. Particle size uniformity ensures precise dosing, which forms a backbone for successful formulation, whether in oral solid dosage or in research laboratory settings. Some suppliers offer it in pre-measured liter solutions for industrial testing, though the solid powder dominates in global trade flows. Small-scale synthesis, bulk pharmaceutical manufacturing, and analytical applications all converge around the demand for consistent, high-grade crystalline powder. The raw material imports and exports track under HS Code 29349990 (other heterocyclic compounds), streamlining regulatory audits and customs filings internationally.
Working with bumetanide calls for deep understanding of its safety profile. Classified as hazardous under several chemical safety frameworks, bumetanide demands gloves, goggles, and ventilation during handling. Potential hazards include moderate irritation to skin, eyes, and respiratory tract on direct exposure. Prolonged contact or improper disposal can trigger environmental and occupational health issues, so chemical waste protocols are non-negotiable. Handlers should consult standardized material safety data sheets and maintain clearly labeled containers to ensure no accidental ingestion or inhalation occurs. Emergency response and spill procedures also bring peace of mind, especially in busy labs or production sites.
Beyond pharmaceuticals, bumetanide slots into many chemical research initiatives, especially where testing or calibrating ion transport in biological and synthetic models is required. Its raw material status cements its spot in supply chains, linking manufacturing hubs in China, Europe, and North America. Suppliers and buyers juggle purity demands, regulatory scrutiny, and hazardous labeling during transport and storage. Its relatively high density makes bulk handling cost-effective for large-scale output. The granulated solid form makes it easier to measure and mix into complex formulations, while long-term shelf stability bolsters its commercial value.
Handling any active pharmaceutical ingredient, including bumetanide, brings a wake-up call to best practices in safety and sustainability. The industry could benefit from expanding closed-system synthesis and recovery equipment, recycling solvents more systematically, and designing storage protocols that slash chemical waste. Clear hazard communication saves lives in the lab, and careful attention to global regulations—like REACH in Europe or TSCA in the United States—keeps supply chains compliant and trustworthy. It is through this attention to detail, hands-on safety, and transparent sourcing that manufacturers, scientists, and regulators achieve safer outcomes for workers, end-users, and the environment.
